Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02274987 · ClinicalTrials.gov registry record · NA

Molecular Profiling for Individualized Treatment Plan for DIPG

A NA study of Diffuse Intrinsic Pontine Glioma (DIPG), sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
38
Enrollment target
5
Study locations

NCT02274987 is a NA study of Diffuse Intrinsic Pontine Glioma (DIPG) that has completed, run by University of California, San Francisco. The registered enrollment target is 38 participants. The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02274987, a NA study of Diffuse Intrinsic Pontine Glioma (DIPG), has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
5
Study locations

Study Summary

This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.

Interventions

  • OTHER Specialized tumor board recommendation
  • RADIATION Standard radiation therapy

Study Locations (5)

California

  • Rady Children's Hospital - San Diego
  • University of California, San Francisco - San Francisco

District of Columbia

  • Children's National Medical Center - Washington D.C.

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2014-09-16
Est. Completion 2019-02-24
Phase NA

What the Registry Record Tells You About NCT02274987

The ClinicalTrials.gov registry entry for NCT02274987 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Intrinsic Pontine Glioma (DIPG) appearing as the primary indexed condition, and to 2 interventions - of which Specialized tumor board recommendation is the first listed.

NCT02274987 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, District of Columbia, Illinois.

Frequently Asked Questions

What is clinical trial NCT02274987 about?

NCT02274987 is a clinical study titled "Molecular Profiling for Individualized Treatment Plan for DIPG". This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.

What is the current status of trial NCT02274987?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2014-09-16. Estimated completion is 2019-02-24.

What conditions does trial NCT02274987 study?

This clinical trial studies the following conditions: Diffuse Intrinsic Pontine Glioma (DIPG).

What interventions are being tested in trial NCT02274987?

The interventions under investigation include: Specialized tumor board recommendation (OTHER), Standard radiation therapy (RADIATION).

Who is sponsoring clinical trial NCT02274987?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02274987 being conducted?

This trial has 5 study locations across California, District of Columbia, Illinois, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diffuse Intrinsic Pontine Glioma (DIPG)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.